Summary
There is no cure for chronic heart disease. Instead, it is crucial to detect early signs of worsening and to manage the disease over time. Even when chronic heart patients have cardiac implanted electronic devices (CIED), dangerous arrhythmia still occur and leads to early deaths and dramatically reduce patients’ quality of life. Today, hospitals carry out partly remote follow-ups on these life-threatening situations. But current systems are disease oriented (focus is on managing symptoms, not preventing them) and are designed for reactive care (only intervene after symptoms have manifested and unable to predict arrhythmia).
Vital Beats has developed a state-of-the-art patient-centered, AI-driven clinical decision-support tool (SCAUT DECISIO) for preventing life-threatening arrhythmia in CIED patients. By combining patient-clinician communication with predictive AI algorithms, we can effectively and efficiently predict life-threatening arrythmias up to 30 days in advance, thereby allowing early and appropriate interventions to be taken. SCAUT DECISIO minimizes the number of CIED patients experiencing life-threatening arrhythmia – and eventual death – by 20%. This results in (1) improved quality of life for patients, (2) improved quality of care, and (3) reduced healthcare costs. SCAUT DECISIO will revolutionise chronic care and finally enable truly personalized and preventive care for chronic heart patients.
To date, Vital Beats has raised more than €4M in total funding to bring the pilot product to its first test at the Heart Centre at Rigs Hospital in Denmark. The EIC Accelerator will be a key de-risking step, which will enable Vital Beats to validate their platform, obtain regulatory approval needed to be ready for global commercialisation. Vital Beats seeks €2.38M to critically de-risk and allow for international commercialisation. Upon completion, Vital Beats will launch SCAUT DECISIO in the Nordic market, then the European market and ultimately enter the US.
Vital Beats has developed a state-of-the-art patient-centered, AI-driven clinical decision-support tool (SCAUT DECISIO) for preventing life-threatening arrhythmia in CIED patients. By combining patient-clinician communication with predictive AI algorithms, we can effectively and efficiently predict life-threatening arrythmias up to 30 days in advance, thereby allowing early and appropriate interventions to be taken. SCAUT DECISIO minimizes the number of CIED patients experiencing life-threatening arrhythmia – and eventual death – by 20%. This results in (1) improved quality of life for patients, (2) improved quality of care, and (3) reduced healthcare costs. SCAUT DECISIO will revolutionise chronic care and finally enable truly personalized and preventive care for chronic heart patients.
To date, Vital Beats has raised more than €4M in total funding to bring the pilot product to its first test at the Heart Centre at Rigs Hospital in Denmark. The EIC Accelerator will be a key de-risking step, which will enable Vital Beats to validate their platform, obtain regulatory approval needed to be ready for global commercialisation. Vital Beats seeks €2.38M to critically de-risk and allow for international commercialisation. Upon completion, Vital Beats will launch SCAUT DECISIO in the Nordic market, then the European market and ultimately enter the US.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/961480 |
| Start date: | 01-07-2020 |
| End date: | 30-06-2022 |
| Total budget - Public funding: | 2 742 500,00 Euro - 1 919 750,00 Euro |
Cordis data
Original description
There is no cure for chronic heart disease. Instead, it is crucial to detect early signs of worsening and to manage the disease over time. Even when chronic heart patients have cardiac implanted electronic devices (CIED), dangerous arrhythmia still occur and leads to early deaths and dramatically reduce patients’ quality of life. Today, hospitals carry out partly remote follow-ups on these life-threatening situations. But current systems are disease oriented (focus is on managing symptoms, not preventing them) and are designed for reactive care (only intervene after symptoms have manifested and unable to predict arrhythmia).Vital Beats has developed a state-of-the-art patient-centered, AI-driven clinical decision-support tool (SCAUT DECISIO) for preventing life-threatening arrhythmia in CIED patients. By combining patient-clinician communication with predictive AI algorithms, we can effectively and efficiently predict life-threatening arrythmias up to 30 days in advance, thereby allowing early and appropriate interventions to be taken. SCAUT DECISIO minimizes the number of CIED patients experiencing life-threatening arrhythmia – and eventual death – by 20%. This results in (1) improved quality of life for patients, (2) improved quality of care, and (3) reduced healthcare costs. SCAUT DECISIO will revolutionise chronic care and finally enable truly personalized and preventive care for chronic heart patients.
To date, Vital Beats has raised more than €4M in total funding to bring the pilot product to its first test at the Heart Centre at Rigs Hospital in Denmark. The EIC Accelerator will be a key de-risking step, which will enable Vital Beats to validate their platform, obtain regulatory approval needed to be ready for global commercialisation. Vital Beats seeks €2.38M to critically de-risk and allow for international commercialisation. Upon completion, Vital Beats will launch SCAUT DECISIO in the Nordic market, then the European market and ultimately enter the US.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
